{
    "nctId": "NCT03523299",
    "briefTitle": "Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer",
    "officialTitle": "Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Invasive Ductal Carcinoma, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Incidence of treatment-emergent adverse events [safety]",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ultrasound visible invasive ductal carcinoma (IDC) diagnosed by core needle biopsy;\n* Tumor visible by ultrasound at time of treatment;\n* Unifocal primary disease;\n* Tumor size between 0.5 cm and 2.0 cm (as measured on ultrasound);\n* Tumor depth \u2265 0.5 cm from the skin or nipple-areola complex;\n* Planned lumpectomy\n\nExclusion Criteria:\n\n* Pregnant patients\n* Multifocal or metastatic disease\n* Planned neoadjuvant chemotherapy or radiation\n* Extensive ductal carcinoma in situ (DCIS; \\>25% DCIS component) either diagnosed on core biopsy or strongly suggested by imaging\n* Known allergy to both lidocaine and benzocaine",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}